Top

Drugs & Aging

Published in:

01-01-2000 | Review Article

Insulin-Like Growth Factor I

Implications in Aging

Authors: Emanuela Arvat, Fabio Broglio, Dr Ezio Ghigo

Published in: Drugs & Aging | Issue 1/2000

Abstract

According to the somatomedin model, growth hormone (GH)-dependent hepatic synthesis is responsible for maintaining circulating insulin-like growth factor (IGF)-I levels. On the other hand, the local autocrine/paracrine IGF-I expression in peripheral tissue is generally GH-independent and reflects the effects of various and tissue-specific trophic hormones.

Circulating IGF-I levels undergo important age-related variations increasing at puberty and decreasing, thereafter, to low levels in the elderly. Low IGF-I levels in the elderly mainly reflect impaired somatotroph secretion but the decline in gonadal sex steroid levels, some protein and micronutrients malnutrition as well as age-dependent variations in IGF-binding proteins may also play a role in the age-related decrease in IGF-I activity. This, in turn, partially accounts for age-related changes in bones, muscles, cardiovascular system, central nervous system and the immune system. However, it is currently unclear whether treatment with exogenous IGF-I can retard or reverse age-related changes in body structure and function.

Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16(1): 3–34PubMed

Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18(6): 801–31PubMedCrossRef

Baxter RC. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand 1991; 372 Suppl.: 107–14CrossRef

Rosen CJ, Conover C. Growth hormone/insulin-like growth factor-I axis in aging: a summary of a National Institutes of Aging-Sponsored Symposium. J Clin Endocrinol Metab 1997; 82(12): 3919–22PubMedCrossRef

Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995; 80(8): 2534–42PubMedCrossRef

Noll K, Wegmann BR, Havemann K, et al. Insulin-like growth factors stimulate the release of insulin-like growth factor-binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in nonsmall cell lung cancer cell lines. J Clin Endocrinol Metab 1996; 81(7): 2653–62PubMedCrossRef

Benbassat CA, Maki KC, Unterman TG. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. J Clin Endocrinol Metab 1997; 82(5): 1484–91PubMedCrossRef

Lee PDK, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med 1993; 204: 4–29PubMed

Suikkari AM, Koivisto V, Rutanen EM, et al. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988; 66: 266–72PubMedCrossRef

10.

Holly JMP, Smith CP, Dunger DB, et al. Levels of the small insulin-like growth factor binding protein are strongly related to those of insulin in prepubertal and pubertal children but only weakly so after puberty. J Endocrinol 1989; 121: 383–7PubMedCrossRef

11.

Conover CA, Butler PC, Wang M, et al. Lack of growth hormone effect on insulin-associated suppression of insulin-like growth factor binding protein 1 in humans. Diabetes 1990; 39: 1251–6PubMedCrossRef

12.

Lewitt MS, Baxter RC. Regulation of growth hormone-independent insulin-like growth factor-binding protein (PB-28) in cultured human fetal liver explants. J Clin Endocrinol Metab 1989; 69: 246–52PubMedCrossRef

13.

Yamamoto H, Sohmiya M, Oka N, et al. Effects of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults. Acta Endocrinol 1991; 124: 497–500PubMed

14.

Clemmons DR, Van Wyk JJ. Factors controlling blood concentration of somatomedin C. J Clin Endocrinol Metab 1984; 13(1): 113–43CrossRef

15.

Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987; 64(1): 51–8PubMedCrossRef

16.

Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78(3): 744–52PubMedCrossRef

17.

Hammerman MR. Insulin-like growth factors and aging. Endocrinol Metab Clin North Am 1987; 16(4): 995–1011PubMed

18.

Toogood AA, O’Neill PA, Shalet SM. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996; 81(2): 460–5PubMedCrossRef

19.

Ghigo E, Arvat E, Goffi S, et al. Neural control of growth hormone secretion in aged humans. In: Muller EE, Cocchi D, Locatelli V, editors. Growth hormone and somatomedins during lifespan. Berlin: Springer Verlag, 1993: 275–87CrossRef

20.

Janssen JA, Stolk RP, Pols HAP, et al. Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroids levels. Clin Endocrinol 1998; 48: 471–8CrossRef

21.

Janssen JA, Jacobs ML, Derkx FHM, et al. Free and total insulinlike growth factor-I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2809–15PubMedCrossRef

22.

Frystyk J, Skjaerbaek C, Dinesen B, et al. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 1994; 348(2): 185–91PubMedCrossRef

23.

Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14(1): 20–39PubMed

24.

Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991; 73(5): 1081–8PubMedCrossRef

25.

Ghigo E, Arvat E, Gianotti L, et al. Human aging and the GHIGF-I axis. J Pediatr Endocrinol Metab 1996; 9Suppl. 3: 271–8PubMed

26.

Ghigo E, Goffi S, Nicolosi M, et al. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. J Clin Endocrinol Metab 1990; 71: 1481–5PubMedCrossRef

27.

Ghigo E, Arvat E, Muccioli G, et al. Growth hormone-releasing peptides. Eur J Endocrinol 1997; 136: 445–60PubMedCrossRef

28.

Arvat E, Gianotti L, Grottoli S, et al. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. J Clin Endocrinol Metab 1994; 79: 1440–3PubMedCrossRef

29.

Ghigo E, Arvat E, Gianotti L, et al. Aging and GH-releasing peptides. In: Bercu B, Walker R, editors. Growth hormone secretagogues. New York: Springer-Verlag, 1996: 415–31CrossRef

30.

Arvat E, Camanni F, Ghigo E. Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Acta Paediatr Suppl 1997; 423: 92–6PubMedCrossRef

31.

Ghigo E, Arvat E, Gianotti L, et al. Short-term administration of intranasal or oral hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol 1996; 135(4): 407–12PubMedCrossRef

32.

Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81: 4249–57PubMedCrossRef

33.

Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology 1997; 66: 278–86PubMedCrossRef

34.

O’Connor K, Stevens TE, Blackman MR. Growth hormone and aging. In: Juul A, Jørgersen JOL, editors. Growth Hormone in adults: physiological and clinical aspects. Cambridge: Cambridge University Press, 1996: 323–66

35.

Lieberman SA, Mitchell AM, Marcus R, et al. The insulin-like growth factor I generation test: resistance to growth hormone with aging and estrogen replacement therapy. Horm Metab Res 1994; 26(5): 229–33PubMedCrossRef

36.

Arvat E, Ceda G, Ramunni J, et al. The IGF-I response to very low rhGH doses is preserved in human aging. Clin Endocrinol 1998; 49: 757–63CrossRef

37.

Chapman IM, Hartman ML, Pezzoli SS, et al. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback. J Clin Endocrinol Metab 1997; 82(9): 2996–3004PubMedCrossRef

38.

De Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995; 16(1): 63–86PubMedCrossRef

39.

Rudman D. Growth hormone, body composition and aging. J Am Geriatr Soc 1985; 33: 800–7PubMed

40.

Smith RG, Van der Ploeg LHT, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997; 18(5): 621–45PubMedCrossRef

41.

Ghigo E, Arvat E, Aimaretti G, et al. Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Baillieres Clin Endocrinol Metab 1998; 12(2): 341–58PubMedCrossRef

42.

Thissen J, Keteslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80–101PubMed

43.

Ross RJM, Chew SL. Acquired growth hormone resistance. Eur J Endocrinol 1995; 132: 655–60PubMedCrossRef

44.

Underwood LE, Thissen JP, Lemozy S, et al. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 1994; 42: 145–51PubMedCrossRef

45.

Clemmons DR, Underwood LE. Nutritional regulation of IGFI, and IGF binding proteins. Annu Rev Nutr 1991; 11: 393–412PubMedCrossRef

46.

Ninh NX, Thissen JP, Maiter D, et al. Reduced liver IGF-I gene expression in young zinc deprived rats is associated with a decrease in liver GH receptors and serum GH binding protein. J Endocrinol 1995; 144: 449–54PubMedCrossRef

47.

Devine A, Rosen C, Mohan S, et al. Effects of zinc and other nutritional factors on insulin-like growth factor I and insulin-like growth factor binding proteins in postmenopausal women. Am J Clin Nutr 1998; 68(1): 200–6PubMed

48.

Johnson TR, Blossey BK, Denko CW, et al. Expression of insulin-like growth factor-I in cultured rat hepatocytes: effects of insulin and growth hormone. Mol Endocrinol 1989; 3: 580–7PubMedCrossRef

49.

Boni-Schnetzler M, Schmid C, Meier PJ, et al. Insulin regulates insulin-like growth factor-I mRNA in rat hepatocytes. Am J Physiol 1991; 260: E846–51PubMed

50.

Scott CD, Baxter RC. Production of insulin-like growth factor I and its binding protein in rat hepatocytes cultured from diabetic and insulin-treated diabetics rats. Endocrinology 1986; 119: 2346–52PubMedCrossRef

51.

Daughaday WH, Phillips LS, Mueller MC. The effects of insulin and growth hormone on the release of somatomedin by the isolated rat liver. Endocrinology 1976; 98: 1214–19PubMedCrossRef

52.

Phillips LS, Goldstein S, Pao CI. Nutrition and somatomedin: XXVI. Molecular regulation of IGF-I by insulin in cultured rat hepatocytes. Diabetes 1991; 40: 1525–30PubMedCrossRef

53.

Houston B, O’Neill IE. Insulin and growth hormone act synergistically to stimulate insulin-like growth factor-I production by cultured chicken hepatocytes. J Endocrinol 1991; 128: 389–93PubMedCrossRef

54.

Phillips LS, Young HS. Nutrition and somatomedin: II. Serum somatomedin activity and cartilage growth activity in streptozotocin-diabetic rats. Diabetes 1976; 25: 516–27PubMedCrossRef

55.

Maes M, Ketesleger JM, Underwood LE. Low plasma soma-tomedin-C in streptozotocin-induced diabetes mellitus: correlation with changes in somatogenic and lactogenic liver binding sites. Diabetes 1983; 32: 1060–9PubMedCrossRef

56.

Brismar K, Fernqvist-Forbes E, Wahren J, et al. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994; 79: 872–8PubMedCrossRef

57.

Maiter D, Fliesen T, Underwood LE, et al. Dietary protein restriction decreases insulin-like growth factor I independent of insulin and liver growth hormone binding. Endocrinology 1989; 124(5): 2604–11PubMedCrossRef

58.

Baxter RC, Bryson JM, Turtle JR. Somatogenic receptors of rat liver: regulation by insulin. Endocrinology 1980; 107: 1176–81PubMedCrossRef

59.

Giacca A, Fisher SJ, Shi ZQ, et al. Insulin-like growth factor-I and insulin have no differential effects on glucose production and utilization under conditions of hyperglycemia. Endocrinology 1994; 134: 2251–8PubMedCrossRef

60.

Lang CH, Fan J, Frost RA, et al. Regulation of the insulin-like growth factor system by insulin in burn patients. J Clin Endocrinol Metab 1996; 81: 2474–80PubMedCrossRef

61.

Powell DR, Suwanichkul A, Cubbage ML, et al. Insulin inhibits transcription of the human gene for insulin-like growth factor binding protein-1. J Biol Chem 1991; 266: 18868–76PubMed

62.

Hall K, Brismar K, Grissom F, et al. IGFBP-1: production and control mechanisms. Acta Endocrinol (Copenh) 1991; 124: 46–54

63.

Bar RS, Boes M, Clemmons DR, et al. Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart. Endocrinology 1990; 127: 497–9PubMedCrossRef

64.

Rutanen EM, Karkkainen T, Stenman UH, et al. Aging is associated with decreased suppression of insulin-like growth factor binding protein-1 by insulin. J Clin Endocrinol Metab 1993; 77(5): 1152–5PubMedCrossRef

65.

Gregoire Nyomba BL, Berard L, Murphy LJ. Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 2177–81CrossRef

66.

Bereket A, Lang CH, Fan J, et al. Insulin-like growth factor binding protein (IGFBP)-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995; 80: 2282–8PubMedCrossRef

67.

Martin FC, Yeo AL, Sonksen PH. Growth hormone secretion in the elderly: ageing and the somatopause. Baillieres Clin Endocrinol Metab 1997; 11(2): 223–50PubMedCrossRef

68.

Hernandez ER. Regulation of genes for insulin-like growth factor (IGF) I and II and their receptors by steroids and gonadotropins in the ovary. J Steroid Biochem Mol Biol 1995; 53: 219–1PubMedCrossRef

69.

Attie KM, Ramirez NR, Conte FA, et al. The pubertal growth spurt in eight patients with true precocious puberty and growth hormone deficiency: evidence for a direct role of sex steroids. J Clin Endocrinol Metab 1990; 71: 975–83PubMedCrossRef

70.

Gabrielsson BG, Carmignac DF, Flavell DM, et al. Steroid regulation of growth hormone (GH) receptor and GH-binding protein messenger ribonucleic acids in the rat. Endocrinology 1995; 136: 209–17PubMedCrossRef

71.

Kelly JJ, Rajkovic IA, O’Sullivan, et al. Effects of different oral oestrogen formulations on insulin-like growth factor-1, growth hormone and growth hormone binding protein in postmenopausal women. Clin Endocrinol (Oxf) 1993; 39(5): 561–7CrossRef

72.

Dawson-Hughes B, Stern D, Goldman J, et al. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement therapy. 1986; 63: 424–9

73.

Wiessberger AJ, Ho KK, Lazarus LJ. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor-I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991; 72: 374–81CrossRef

74.

Friend KE, Hartmann ML, Pezzoli SS, et al. Both oral and transdermal estrogen replacement increase GH release in postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 1996; 81: 2250–6PubMedCrossRef

75.

Bellantoni MF, Vittone J, Campfield AT, et al. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 1996; 81(8): 2848–53PubMedCrossRef

76.

Mannor DA, Winer LM, Shaw MA, et al. Plasma growth hormone (GH)-binding proteins: effects on binding to receptors and GH action. J Clin Endocrinol Metab 1991; 73: 30–4PubMedCrossRef

77.

Jørgensen JO, Vahl N, Hansen TB, et al. Determinants of serum insulin-like growth factor I in growth hormone deficient adults as compared to healthy subjects. Clin Endocrinol 1998; 48(4): 479–86CrossRef

78.

Martha PMJ, Rogol AD, Veldhuis JD, et al. Alteration in the pulsatile properties of circulating growth hormone concentration during puberty in boys. J Clin Endocrinol Metab 1989; 69: 563–70PubMedCrossRef

79.

Keenan BS, Richards GE, Mercado M, et al. Androgen regulation of growth hormone binding protein. Metabolism 1996; 45(12): 1521–6PubMedCrossRef

80.

Hobbs CJ, Plymate SR, Rosen CJ, et al. Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 1993; 77: 776–9PubMedCrossRef

81.

Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360–7PubMedCrossRef

82.

Corpas E, Harman SM, Blackman MR. Serum IGF-binding protein-3 is related to IGF-I, but not to spontaneous GH release, in healthy old men. Horm Metab Res 1992; 24(11): 543–5PubMedCrossRef

83.

Juul A, Main K, Blum WF, et al. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994; 41(1): 85–93CrossRef

84.

Juul A, Holm K, Kastrup KW, et al. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab 1997; 82(8): 2497–502PubMedCrossRef

85.

Collet-Solberg PF, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF-I action. Endocrinol Metab Clin North Am 1996; 25: 591–614CrossRef

86.

Bang P. Serum proteolysis of IGFBP-3. Prog Growth Factor Res 1995; 6: 285–92PubMedCrossRef

87.

Conover CA. Insulin-like growth factor binding protein proteolysis in bone cell models. Prog Growth Factor Res 1995; 6: 301–9PubMedCrossRef

88.

Angelloz-Nicoud P, Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 1995; 136: 5485–92PubMedCrossRef

89.

Sonntag WE, Lynch CD, Bennet SA, et al. Alterations in insulin-like growth factor-1 gene and protein expression and type 1 insulin-like growth factors receptors in the brains of ageing rats. Neuroscience 1999; 88(1): 269–79PubMedCrossRef

90.

Dore S, Kar S, Rowe W, et al. Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Neuroscience 1997; 80(4): 1033–40PubMedCrossRef

91.

Stenvers KL, Lund PK, Gallagher M. Increased expression of type 1 insulin-like growth factor receptor messenger RNA in rat hippocampal formation is associated with aging and behavioral impairment. Neuroscience 1996; 72(2): 505–18PubMedCrossRef

92.

De Keyser J, Wilczac N, Goossens A. Insulin-like growth factor-I receptor densities in human frontal cortex and white matter during aging, in Alzheimer’s disease, and in Huntington’s disease. Neurosci Lett 1994; 172(1-2): 93–6PubMedCrossRef

93.

Willis PE, Chadan S, Baracos V, et al. Acute exercise attenuates age-associated resistance to insulin-like growth factor I. Am J Physiol 1997; 272 (3 Pt 1): E397–404PubMed

94.

Renganathan M, Sonntag WE, Delbono O. L-type Ca2+ channel-insulin-like growth factor-1 receptor signaling impairment in aging rat skeletal muscle. Biochem Biophys Res Commun 1997; 235(3): 784–9PubMedCrossRef

95.

Willis PE, Chadan SG, Baracos V, et al. Restoration of insulin-like growth factor I action in skeletal muscle of old mice. Am J Physiol 1998; 275 (3 Pt 1): E525–30PubMed

96.

Tanaka H, Liang CT. Mitogenic activity but not phenotype expression of rat osteoprogenitor cells in response to IGF-I is impaired in aged rats. Mech Ageing Dev 1996; 92(1): 1–10PubMedCrossRef

97.

Pfeilschifter J, Diel I, Pilz U, et al. Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age. J Bone Miner Res 1993; 8(6): 707–17PubMedCrossRef

98.

D’avis PY, Frazier CR, Shapiro JR, et al. Age-related changes in effects of insulin-like growth factor I on human osteoblastlike cells. Biochem J 1997 15; 324 Pt 3: 753–60

99.

Schachtschabel DO, Freudenstein G. Diminished stimulation of hyaluronic acid synthesis by PDGF, IGF-I or serum in the senescence phase of skin fibroblast in vitro. Zeitschrift Gerontol 1994; 27(3): 177–81

100.

Boulware SD, Tamborlane WV, Rennert NJ, et al. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin: dose-response relationship in healthy young and middle aged adults. J Clin Invest 1994; 93(3): 1131–9PubMedCrossRef

101.

Canalis E. Skeletal growth factors and aging. J Clin Endocrinol Metab 1994; 78(5): 1009–10PubMedCrossRef

102.

Ravn P, Overgaard K, Spencer EM, et al. Insulin-like growth factors I and II in healthy women with and without established osteoporosis. Eur J Endocrinol 1995; 132(3): 313–9PubMedCrossRef

103.

Johansson AG, Eriksen EF, Lindh E, et al. Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men. J Clin Endocrinol Metab 1997; 82(9): 2795–8PubMedCrossRef

104.

Kurland ES, Chan FKW, Rosen CJ, et al. Normal Growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 1988; 83(7): 2576–9CrossRef

105.

Sugimoto T, Nishiyama K, Kuribayashi F, et al. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 1997; 12(8): 1272–9PubMedCrossRef

106.

Boonen S, Lesaffre E, Dequeker J, et al. Relationship between baseline insulin-like growth factor-I (IGF-I) and femoral bone density in women aged over 70 years: potential implications for the prevention of age-related bone loss. J Am Geriatr Soc 1996; 44(11): 1301–6PubMed

107.

Kassem M, Brixen K, Blum W, et al. No evidence for reduced spontaneous or growth hormone stimulated serum levels of insulin-like growth factor (IGF)-I, IGF-II or IGF binding protein 3 in women with spinal osteoporosis. Eur J Endocrinol 1994; 131: 150–5PubMedCrossRef

108.

Bennett AE, Wahner HW, Riggs BL, et al. Insulin-like growth factors I and II: aging and bone density in women. J Clin Endocrinol Metab 1984; 59(4): 701–4PubMedCrossRef

109.

Pfeilschifter J, Ziegler R. Relationship between IGF-I and skeletal aging. Eur J Endocrinol 1998; 138(6): 617–8PubMedCrossRef

110.

Moreira-Andres MN, Papapietro K, Canizo FJ, et al. Correlations between bone mineral density, insulin-like growth factor I and auxological variables. Eur J Endocrinol 1995; 132(5): 573–9PubMedCrossRef

111.

Janssen JA, Burger H, Stolk RP, et al. Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. Eur J Endocrinol 1998; 138(6): 627–32PubMedCrossRef

112.

Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G, et al. Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50- to 80-year-old men and women. J Clin Endocrinol Metab 1996; 81: 2534–40PubMedCrossRef

113.

Seck T, Scheppach B, Scharla S, et al. Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J Clin Endocrinol Metab 1998; 83(7): 2331–7PubMedCrossRef

114.

Nicolas V, Prewett A, Bettica P, et al. Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab 1994; 78(5): 1011–6PubMedCrossRef

115.

Boonen S, Aerssens J, Dequeker J, et al. Age-associated decline in human femoral neck cortical and trabecular content of insulin-like growth factor I: potential implications for age-related (type II) osteoporotic fracture occurrence. Calcif Tissue Int 1997; 61(3): 173–8PubMedCrossRef

116.

Rosen CJ, Donahue LR, Hunter SJ. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med 1994; 206: 83–102PubMedCrossRef

117.

Boonen S, Aerssen J, Dequeker J. Age-related endocrine deficiencies and fractures of the proximal femur: I Implications of growth hormone deficiency in the elderly. J Endocrinol 1996; 149: 7–12PubMedCrossRef

118.

Eriksen EF, Kassem M, Brixen K. Growth hormone and insulin-like growth factors as anabolic therapies for osteoporosis. Horm Res 1993; 40: 95–8PubMedCrossRef

119.

Janssen JA, Stolk RP, Pols HA, et al. Serum free and total insulin-like growth factor-I, insulin-like growth factor binding protein-1 and insulin-like growth factor binding protein-3 Levels in healthy elderly individuals: relation to self-reported quality of health and disability. Gerontology 1998; 44(5): 277–80PubMedCrossRef

120.

Florini JR, Ewton DZ, Coolican SA. Growth hormone and the Insulin-like growth factor system in myogenesis. Endocr Rev 1996; 17(1): 481–517PubMed

121.

Welle S, Thornton C, Statt M, et al. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab 1996; 81(9): 3239–43PubMedCrossRef

122.

Welle S, Thornton C. Insulin-like factor-I, actin, and myosin heavy chain messenger RNAs in skeletal muscle after an injection of growth hormone in subjects over 60 years old. J Endocrinol 1997; 115: 93–7CrossRef

123.

Taaffe DR, Pruitt L, Reim J, et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab 1994; 79(5): 1361–6PubMedCrossRef

124.

Isgaard J, Nilsson A, Vilkman K, et al. Growth hormone regulates the level of insulin-like growth factor MRNA in rat skeletal muscle. J Endocrinol 1989; 120: 107–112PubMedCrossRef

125.

Isgaard J, Kujacic V, Jennische E, et al. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest 1997; 27: 517–25PubMedCrossRef

126.

Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555–73PubMed

127.

Timsit J, Riou B, Bertherat J, et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest 1990; 86: 507–15PubMedCrossRef

128.

Mathews LS, Enberg B, Norstedt G. Regulation of rat growth hormone receptors gene expression. J Biol Chem 1989; 17: 9905–10

129.

Sklar MM, Kiess W, Thomas CL, et al. Developmental expression of the tissue insulin-like growth factor II/mannose 6-phosphate receptor in the rat. J Biol Chem 1989; 264: 16733–8PubMed

130.

Engelmann GL, Boehm KD, Haskell JF, et al. Insulin-like growth factors and neonatal cardiomyocyte development: ventricular gene expression and membrane receptor variations in normotensive and hypertensive rats. Mol Cell Endocrinol 1989; 63: 1–14PubMedCrossRef

131.

Guse AH, Kiess W, Funk B, et al. Identification and characterization of insulin-like growth factor receptors on adult rat cardiac myocytes: linkage to inositol 1,4,5-trisphosphate formation. Endocrinology 1992; 130: 145–51PubMedCrossRef

132.

Donath MY, Gosteli-Peter MA, Froesch ER, et al. Insulin-like growth factor-I stimulates myofibrillar genes and modulates atrial natriuretic factor MRNA in rat heart. Eur J Endocrinol 1997; 137: 309–15PubMedCrossRef

133.

Donath MY, Jenni R, Brunner HP, et al. Cardiovascular and metabolic effects of insulin-like growth factor-I at rest and during exercise in humans. J Clin Endocrinol Metab 1996; 81(11): 4089–94PubMedCrossRef

134.

Donath MY, Sutsch G, Yan XW, et al. Acute cardiovascular effects of insulin-like growth factor-I in patients with chronic heart failure. J Clin Endocrinol Metab 1998; 83(9): 3177–83PubMedCrossRef

135.

Hanson MC, Fath KA, Alexander RW, et al. Induction of cardiac insulin-like growth factor 1 gene expression in pressure overload hypertrophy. Am J Med Sci 1993; 306: 69–74PubMedCrossRef

136.

Donohue TJ, Dworkin LD, Lango MN, et al. Induction of myocardial insulin-like growth factor 1 gene expression in left ventricular hypertrophy. Circulation 1994; 89: 799–809PubMedCrossRef

137.

Toyozaki T, Hiroe M, Hasumi M, et al. Insulin-like growth factor 1 receptors in human cardiac myocytes and their relation to myocardial hypertrophy. Jpn Circ J 1993; 57: 1120–7PubMedCrossRef

138.

Buerke M, Murohara T, Skurk C, et al. Cardioprotective effect of insulin-like growth factor-I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A 1995; 92: 8031–5PubMedCrossRef

139.

Walsh MF, Barazi M, Pete G, et al. Insulin-like growth factor-I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996; 137(5): 1798–803PubMedCrossRef

140.

Ceda GP, Dall’Aglio E, Magnacavallo A, et al. The insulin-like growth factor axis and plasma lipid levels in the elderly. J Clin Endocrinol Metab 1998; 83(2): 499–502PubMedCrossRef

141.

Botker HE, Skjaerbaek C, Eriksen UH, et al. Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X. Am J Cardiol 1997; 79(1): 961–3PubMedCrossRef

142.

Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 1996; 77(15): 200–2PubMedCrossRef

143.

Broglio F, Fubini A, Morello M, et al. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol 1999; 50(4): 417–30CrossRef

144.

Muller EE. IGFs in the nervous system. New York (NY): Springer-Verlag, 1998CrossRef

145.

Lopez-Fernandez J, Sanchez-Franco F, Velasco B, et al. Growth hormone induces somatostatin and insulin-like growth factor I gene expression in the cerebral hemispheres of aging rats. Endocrinology 1996; 137(10): 4384–91PubMedCrossRef

146.

D’Ercole AJ, Ye P, Gutierrez-Ospina G. Use of transgenic mice for understanding the physiology of Insulin-like growth factors. Horm Res 1996; 45(1): 5–7PubMedCrossRef

147.

Delafontaine P, Lou H, Alexander RW, et al. Regulation if insulinlike growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension 1991; 18: 742–7PubMedCrossRef

148.

Hansson HA, Jennische E, Skottner A. IGF-1 expression in blood vessels varies with vascular load. Acta Physiol Scand 1987; 129: 165–9PubMedCrossRef

149.

Hansson HA, Brandsten C, Lossing C, et al. Transient expression of insulin-like growth factor I immunoreactivity by vascular cells during angiogenesis. Exp Mol Pathol 1989; 50: 125–38PubMedCrossRef

150.

Sato Y, Okamura K, Morimoto A, et al. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 1993; 204: 223–9PubMedCrossRef

151.

Grant MB, Mames RN, Fitzgerald C, et al. Insulin-like growth factor-I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1993; 36: 282–91PubMedCrossRef

152.

Nakao-Hayashi J, Ito H, Kanayasu T, et al. Stimulators effects of insulin and insulin-like growth factor-I on migration and tube formation by vascular endothelial cells. Atherosclerosis 1992; 92: 141–9PubMedCrossRef

153.

Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-I promote rat aortic angiogenesis in vitro. Am J Pathol 1994; 145: 1023–9PubMed

154.

Sonntag WE, Lynch CD, Cooney PT, et al. Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. Endocrinology 1997; 138(8): 3515–20PubMedCrossRef

155.

Gelato MC. Aging and immune function: a possible role for growth hormone. Horm Res 1996; 45(1-2): 46–9PubMedCrossRef

156.

Clark R. The somatogenic hormones and Insulin-like growth factor-I: of lymphopoiesis and immune function. Endocr Rev 1997; 18(2): 157–79PubMedCrossRef

157.

Krishnaraj R, Zaks A, Unterman T. Relationship between plasma IGF-I levels, in vitro correlates of immunity, and human senescence. Clin Immunol Immunopathol 1998; 88(3): 264–70PubMedCrossRef

Title: Insulin-Like Growth Factor I
Implications in Aging
Authors: Emanuela Arvat
Fabio Broglio
Dr Ezio Ghigo
Publication date: 01-01-2000
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 1/2000
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200016010-00003

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2000

Management of Chronic Lymphocytic Leukaemia

Bone and Joint Infections in the Elderly

β-Blockers For Congestive Heart Failure

Thrombolytic Therapy for Stroke

Comparative Tolerability of the Newer Generation Antiparkinsonian Agents

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials